Stephanie Key's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Bispecific antibodies (BsAb) that engage multiple pathways are a promising therapeutic strategy to improve and prolong the efficacy of biologics in complex diseases. In the early stages of discovery, BsAbs often exhibit a broad range of pharmacokinetic (PK) behavior. Optimization of the neonatal Fc receptor (FcRn) interactions and removal of undesi...
Citations
... 5,6 The slow clinical success of BsAbs can be attributed to several factors, including increased structural complexity leading to greater challenges in their CMC properties, and in their pharmacokinetic (PK) profiles. 7,8 PK of mAbs is characterized by a slow systemic clearance and a long terminal elimination half-life, which is primarily governed by their ability to bind to and recycle through the neonatal Fc receptor (FcRn)-mediated recycling pathway. 9 The FcRn-mediated recycling mechanism involves the nonspecific pinocytosis of IgG and albumin into cells, their binding to FcRn in acidic endosomes, and their subsequent recycling back to the cell surface at neutral pH. ...
